Lugano, Switzerland, 17 April 2023 – The ESMO Breast Cancer Congress 2023, will be held onsite in Berlin, Germany, and online, through a virtual platform, between 11-13 May 2023.
Programme highlights
-
New drugs on the horizon and latest clinical data to optimise clinical decisions
Sessions: Proffered paper 1, Proffered paper 2: Best abstracts and Novel endocrine therapies -
Clinical impact of evolving antibody drug conjugates technology in HER2 non overexpressing breast cancers
Session: HER2 and beyond: The role for antibody drug conjugates (ADCs) in HER2 non overexpressing breast cancers -
Towards personalised therapeutic approaches for better outcomes:
-
Moving away from one size fits all for triple-negative breast cancer
Session: Optimal treatment strategies in early breast cancer -
The importance to identify subsets that benefit from immuno-oncology
Sessions: Refining checkpoint inhibition in triple-negative breast cancer (TNBC) and New comers in the early breast cancer setting: Checkpoint and PARP inhibitors -
How to select biomarkers to inform neoadjuvant strategies and improve treatment options for HER2 positive breast cancer patients
Session: Selecting biomarkers to inform neoadjuvant strategies -
New insights on endocrine therapy resistance and strategies to personalise the treatment of HR+/HER2- metastatic breast cancer
Session: Optimal sequencing in advanced luminal breast cancer -
Adjusting treatment to patient adiposity
Session: Precision/personalised breast cancer medicine: Where do we stand -
Suggested screening methods for women under 50 years and for those over 74 years of age
Session: Patient advocacy
-
-
Adding the patient voice to science: what impact can it have on research?
Session: Bringing the patient voice to cancer research
-
How real-world data can help to solve the equation between quality, cost and survival
Session: Utility of real-world data
-
Accompanying the long-term healing process and supporting smooth reintegration into daily routine: the role of oncologists and of patient organisations
Session: Beyond breast cancer: Survivorship
Keynote lectures
-
“Keynote lecture title to be announced” by Sara Hurvitz, 2023 ESMO Breast Cancer Award recipient, 11 May 2023, 13:00-13:40 CEST
-
“Building evidence using biomarkers and new statistical methods, from prevention to adjuvant treatment of breast cancer” by Laura Esserman, 11 May 2023, 15:45-16:15 CEST
-
“The future of early cancer detection” by David Crosby, 12 May 2023, 14:00-14:30 CEST
The results of more than 250 studies from various parts of the world will be presented either as oral, mini oral or poster presentations, and published online as a supplement of ESMO Open. The abstract titles can be viewed through the online programme.
Media registration
ESMO welcomes media interested in obtaining information and reporting on cancer issues. Only through the official accreditation process with the media registration form, accredited media representatives will be able to access scientific and educational sessions, posters and e-posters, exhibition and industry satellite symposia, Congress webcasts, as well as embargoed material.
Further information
ESMO Press Office
press@esmo.org
-END-
Notes to Editors
Please make sure to use the official name of the meeting in your reports: ESMO Breast Cancer Congress 2023
The official congress hashtag is #ESMOBreast23. Follow it to stay up to date and use it to take part in the conversation: Twitter, LinkedIn, Instagram, Facebook
About the European Society for Medical Oncology (ESMO)
ESMO is the leading professional organisation for medical oncology. With more than 28,000 members representing oncology professionals from 160 countries worldwide, ESMO is the society of reference for oncology education and information. Driven by a shared determination to secure the best possible outcomes for patients, ESMO is committed to standing by those who care about cancer through addressing the diverse needs of #ONEoncologycommunity, offering #educationforLIFE, and advocating for #accessiblecancerCARE. Visit www.esmo.org